These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26770927)

  • 1. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
    Kim GH; Chung JW; Lee JH; Ok KS; Jang ES; Kim J; Shin CM; Park YS; Hwang JH; Jeong SH; Kim N; Lee DH; Kim JW
    Clin Mol Hepatol; 2015 Dec; 21(4):379-86. PubMed ID: 26770927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vegetarian diet does not protect against nonalcoholic fatty liver disease (NAFLD): A cross-sectional study between Buddhist priests and the general population.
    Choi SH; Oh DJ; Kwon KH; Lee JK; Koh MS; Lee JH; Kang HW
    Turk J Gastroenterol; 2015 Jul; 26(4):336-43. PubMed ID: 26039004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association between Vitamin D Insufficiency and Nonalcoholic Fatty Liver Disease: A Population-Based Study.
    Ha Y; Hwang SG; Rim KS
    Nutrients; 2017 Jul; 9(8):. PubMed ID: 28749418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.
    Sonmez A; Nikolic D; Dogru T; Ercin CN; Genc H; Cesur M; Tapan S; Karslioğlu Y; Montalto G; Banach M; Toth PP; Bagci S; Rizzo M
    J Clin Lipidol; 2015; 9(4):576-82. PubMed ID: 26228676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study.
    Erkan G; Sayın I; Polat FB; Çorakçı A; Ataç GK; Değertekin H
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():63-8. PubMed ID: 25910371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
    Anushiravani A; Haddadi N; Pourfarmanbar M; Mohammadkarimi V
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):613-617. PubMed ID: 30920975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
    Younossi ZM; Otgonsuren M; Venkatesan C; Mishra A
    Metabolism; 2013 Mar; 62(3):352-60. PubMed ID: 22999011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
    Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic characteristics and associated factors of nonalcoholic fatty liver disease diagnosed at medical checkups].
    Nah EH; Park JY
    Korean J Lab Med; 2008 Jun; 28(3):244-50. PubMed ID: 18594178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum vitamin-E levels and its relation to clinical features in nonalcoholic fatty liver disease with elevated ALT levels.
    Cankurtaran M; Kav T; Yavuz B; Shorbagi A; Halil M; Coskun T; Arslan S
    Acta Gastroenterol Belg; 2006; 69(1):5-11. PubMed ID: 16673555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
    Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
    J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.